Effects of liraglutide combined with metformin on islet beta cell function and visceral fat level in type 2 diabetes mellitus patients with obesity

doi:10.3877/cma.j.issn.2095-1221.2019.03.003

Abstract

Abstract:

Objective

To analyze the effects of liraglutide combined with metformin on islet beta cell function and visceral fat level in type 2 diabetes mellitus (T2DM) patients with obesity.

Methods

194 patients with T2DM and obesity admitted to our hospital from March 2015 to March 2018 were randomly divided into a study group and a control group (97 cases in each group) . All patients were treated with metformin for 16 weeks. The study group was treated with liraglutide subcutaneously. The changes of blood sugar, pancreatic beta cell function index (HOMA-β) and visceral fat level (VFL) before and after treatment were compared between the two groups, and the clinical value of liraglutide in the treatment of T2DM with obesity was summarized. Chi-square test was used for counting data and t-test was used for measuring data.

Results

The incidence of adverse reactions was 29.90﹪ in the study group and 23.71﹪ in the control group. There was no significant difference between the two groups (χ²= 0.946, P > 0.05) . After treatment, FPG, 2 hPG and BMI of the two groups were all lower than those before treatment, and FPG, 2hPG and BMI in the study group were (7.12±1.35) mmol/L, (9.03±2.66) mmol/L, (26.32±1.60) kg/m², respectively, which were lower than those in the control group (7.83±1.19) mmol/L, (10.57±2.39) ?mmol/?L, (27.74±1.66) ?kg/m², (t = 3.886, 4.241, 6.066, P all < 0.05) . After treatment, HOMA-beta was increased and HOMA-IR was decreased in both groups. After treatment, HOMA-beta in the study group (155.69±24.55) was, higher than that in the control group (117.49±21.98) , and its HOMA-IR (2.30±0.71) was lower than that in the latter group (3.20±0.64) . The difference was statistically significant (t = 11.407, 9.273, P all < 0.05) . The VFL and fat rate of the two groups after treatment were lower than those before treatment. The VFL and fat rate of the study group after treatment were lower than those of the control group, and the muscle content after treatment was lower than that before treatment (P < 0.05) .

Conclusion

Combination of liraglutide with metformin can improve insulin resistance in patients with T2DM and obesity by improving the function of islet beta cells and reducing visceral fat, which is a safe and effective treatment.

Key words: Liraglutide, Metformin, Type 2 diabetes mellitus, Obesity, Islet beta cells, Visceral fat

Hongmin Zhang, Jinlin Wu, Xingyu Zhang, Mei Yang. Effects of liraglutide combined with metformin on islet beta cell function and visceral fat level in type 2 diabetes mellitus patients with obesity[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2019, 09(03): 144-148.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2019.03.003

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2019/V09/I03/144

Figures/Tables 3

References 20

[1]	廖涌. 中国糖尿病的流行病学现状及展望[J]. 重庆医科大学学报, 2015, 40(7):1042-1045.
[2]	Mann JF,Orsted DD,Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes[J]. N Engl J Med, 2017, 377(9):839-848.
[3]	Davies MJ,Bergenstal R,Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes the SCALE diabetes randomized clinical trial[J]. JAMA, 2015, 314(7):687-699.
[4]	Pi-Sunyer X,Astrup A,Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management[J]. N Engl J Med, 2015, 373(1):11-22.
[5]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013年版)[J/ CD]. 中国医学前沿杂志(电子版), 2015, 30(3):26-89.
[6]	Armstrong MJ,Gaunt P,Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet, 2016, 387(119):679-690.
[7]	le Roux CW,Astrup A,Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes:a randomised,double-blind trial[J]. Lancet, 2017, 389(10077):1399-1409.
[8]	Dejgaard TF,Frandsen CS,Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control(Lira-1):a randomised,double-blind, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2016, 4(3):221-232.
[9]	Ahren B,Hirsch IB,Pieber TR, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial[J]. Diabetes Care, 2016, 39(10):1693-1701.
[10]	Iacobellis G,Mohseni M,Bianco SD, et al. Liraglutide causes large and rapid epicardial fat reduction[J]. Obesity, 2017, 25(2):311-316.
[11]	郭洁,孙耀东,边亚, 等. 观察利拉鲁肽对糖尿病病人血脂和超敏C-反应蛋白的影响[J]. 中西医结合心脑血管病杂志, 2016, 14(17):2055-2057.
[12]	Blackman A,Foster GD,Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial[J]. Int J Obes, 2016, 40(8):1310-1319.
[13]	Rizzo M,Abate N,Chandalia M, et al. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes:a prospective pilot study[J]. J Clin Endocrinol Metab, 2015, 100(2):603-606.
[14]	刘琼,卫家芬. 利拉鲁肽治疗糖尿病的研究进展[J]. 河北医药, 2015, 37(5):732-734.
[15]	Santilli F,Simeone PG,Guagnano MT, et al. Effects of liraglutide on weight loss, fat distribution,and β-cell function in obese subjects with prediabetes or early type 2 diabetes[J]. Diabetes Care, 2017, 40(11):1556-1564.
[16]	Farr OM,Sofopoulos M,Tsoukas MA, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled[J]. Diabetologia, 2016, 59(5):954-965.
[17]	蒙光义,彭评志,庞家莲, 等. 利拉鲁肽联合二甲双胍治疗2型糖尿病临床疗效和安全性评估[J]. 医学综述, 2015, 21(17):3223-3226.
[18]	Gao DM,Bao SD. Regulating effect of liraglutide therapy on metabolic disorders in patients with newly diagnosed type 2 diabetes complicated with obesity[J]. Journal of Hainan Medical University, 2017, 23(16):37-40.
[19]	Lingvay I,Desouza CV,Lalic KS, et al. A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin[J]. Diabetes Care, 2018, 41(9):1926-1937.
[20]	Billings LK,Doshi A,Gouet D, et al. Efficacy and safety of IDegLira versus Basal-Bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL Ⅶ randomized clinical trial[J]. Diabetes Care, 2018, 41(5):1009-1016.

分组	FPG （mmol/L）				2 hPG （mmol/L）				BMI （kg/m²）
分组	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
研究组	9.71±1.98	7.12±1.35	10.644	< 0.01	14.76±2.33	9.03±2.66	15.959	< 0.01	29.44±1.92	26.32±1.60	12.295	< 0.01
对照组	9.80±1.72	7.83±1.19	9.277	< 0.01	14.58±2.47	10.57±2.39	11.491	< 0.01	29.12±1.85	27.74±1.66	5.468	< 0.01
t值	0.338	3.886	?	?	0.522	4.241	?	?	1.182	6.066	?	?
P值	0.368	< 0.01	?	?	0.301	< 0.01	?	?	0.119	< 0.01	?	?

分组	FPG （mmol/L）				2 hPG （mmol/L）				BMI （kg/m²）
分组	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
研究组	9.71±1.98	7.12±1.35	10.644	< 0.01	14.76±2.33	9.03±2.66	15.959	< 0.01	29.44±1.92	26.32±1.60	12.295	< 0.01
对照组	9.80±1.72	7.83±1.19	9.277	< 0.01	14.58±2.47	10.57±2.39	11.491	< 0.01	29.12±1.85	27.74±1.66	5.468	< 0.01
t值	0.338	3.886	?	?	0.522	4.241	?	?	1.182	6.066	?	?
P值	0.368	< 0.01	?	?	0.301	< 0.01	?	?	0.119	< 0.01	?	?

分组	HOMA-β				HOMA-IR
分组	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
研究组	102.26±21.37	155.69±24.55	16.168	< 0.01	3.76±1.05	2.30±0.71	11.344	< 0.01
对照组	105.03±20.26	117.49±21.98	4.095	< 0.01	3.71±0.99	3.20±0.64	4.261	< 0.01
t值	0.926	11.407	?	?	0.000	9.273	?	?
P值	0.178	< 0.01	?	?	0.500	< 0.01	?	?

分组	HOMA-β				HOMA-IR
分组	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
研究组	102.26±21.37	155.69±24.55	16.168	< 0.01	3.76±1.05	2.30±0.71	11.344	< 0.01
对照组	105.03±20.26	117.49±21.98	4.095	< 0.01	3.71±0.99	3.20±0.64	4.261	< 0.01
t值	0.926	11.407	?	?	0.000	9.273	?	?
P值	0.178	< 0.01	?	?	0.500	< 0.01	?	?

分组	VFL				脂肪率（﹪）				肌肉含量（kg）
分组	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
研究组	13.15±2.06	9.06±1.81	14.690	< 0.01	32.35±3.17	27.05±2.23	13.468	< 0.01	43.35±8.16	45.49±8.02	1.842	0.033
对照组	13.07±1.95	10.12±1.63	11.432	< 0.01	32.66±3.25	29.72±4.03	5.593	< 0.01	43.71±9.05	44.80±9.27	0.829	0.204
t值	0.278	4.286	?	?	0.673	5.709	?	?	0.291	0.554	?	?
P值	0.391	< 0.01	?	?	0.251	< 0.01	?	?	0.386	0.290	?	?

Please choose a citation manager

Content to export